Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey. Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status. Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC. Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.
Abstract
Background: Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey. Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status. Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC. Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.
참고문헌 (36)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Owonikoko TK, "Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database", J Clin Oncol, 25, pp.5570~5577 (2007)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Rosell R, "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
- Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), 2011, pp.29, 2866~2874
- Yang JC, "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials", Lancet Oncol, 16, pp.141~151 (2015)
- Yatabe Y, "EGFR mutation testing practices within the Asia Pacific region : results of a multicenter diagnostic survey", J Thorac Oncol, 10, pp.438~445 (2015)
- Yang CH, "EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future", Lung Cancer, 60(Suppl 2), pp.S23~S30 (2008)
- Shigematsu H, "Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers", J Natl Cancer Inst, 97, pp.339~346 (2005)
- Skov BG, "The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population", APMIS, 123, pp.108~115 (2015)
- Gahr S, "EGFR mutational status in a large series of Caucasian European NSCLC patients : data from daily practice", Br J Cancer, 109, pp.1821~1828 (2013)
- Soung YH, "Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas", Virchows Arch, 446, pp.483~488 (2005)
- Bae NC, "EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients", Cancer Genet Cytogenet, 173, pp.107~113 (2007)
- Park S, "Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer", J Thorac Oncol, 4, pp.809~815 (2009)
- Lee YJ, "Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma", J Cancer Res Clin Oncol, 135, pp.1647~1654 (2009)
- Ahn MJ, "Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?", Clin Cancer Res, 14, pp.3860~3866 (2008)
- Sun PL, "High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR", TTF-1 expressions, and clinical features, 2012, pp.7, 323~330
- Kim YT, "The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer", J Thorac Oncol, 8, pp.171~178 (2013)
- Choi YL, "EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital", PLoS One, 8, pp.e56011~ (2013)
- Ma BB, "Population-based differences in treatment outcome following anticancer drug therapies", Lancet Oncol, 11, pp.75~84 (2010)
- Chan SK, "Mutations of the epidermal growth factor receptor in non-small cell lung cancer : search and destroy", Eur J Cancer, 42, pp.17~23 (2006)
- Shi Y, "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)", J Thorac Oncol, 9, pp.154~162 (2014)
- Liu J, "ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens", J Cancer Res Clin Oncol, 141, pp.221~227 (2015)
- Heymann JJ, "Molecular testing guidelines for lung adenocarcinoma : utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples", Cytojournal, 11, pp.12~ (2014)
- Khode R, "Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas", Cancer Cytopathol, 121, pp.361~369 (2013)
- Sun PL, "High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas", Cancer Cytopathol, 121, pp.311~319 (2013)
- Pirker R, "Consensus for EGFR mutation testing in non-small cell lung cancer : results from a European workshop", J Thorac Oncol, 5, pp.1706~1713 (2010)
- Pao W, "Epidermal growth factor receptor mutation testing in lung cancer : searching for the ideal method", Clin Cancer Res, 13, pp.4954~4955 (2007)
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Dufort S, "Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC", J Exp Clin Cancer Res, 30, pp.57~ (2011)
- 최재진, "PNA-mediated Real-Time PCR Clamping for Detection of EGFR Mutations", Bulletin of the Korean Chemical Society, 31(12), pp.3525~3529 (2010), 대한화학회
- 이현주, "Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment", Journal of Pathology and Translational Medicine, 47(1), pp.52~60 (2013), 대한병리학회
- Kim HJ, "Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer", Lung Cancer, 75, pp.321~325 (2012)